Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/27/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David M. Kleinman MD MBA

Wrong Dr. David M. Kleinman MD MBA?

Chief Executive Officer

Local Address: Rochester, New York, United States
Eyeon Particle Sciences LLC
 
Background

Employment History

  • President
    Eyeon Therapeutics , Inc.
  • President and Chief Executive Officer
    Eyeon Therapeutics , Inc.
  • President and Co-founder
    Eyeon Therapeutics , Inc.
  • Associate Professor of Ophthalmology (Part Time)
    Flaum Eye Institute at the University of Rochester
  • Associate Professor and Retina Specialist
    Flaum Eye Institute at the University of Rochester
  • University of Rochester
  • Physician
    University of Rochester Medical Center
  • Assistant Professor of Ophthalmology
    University of Rochester Medical Center
  • Retinal Specialist
    University of Rochester Medical Center
  • Director of Ophthalmic Trauma Services and Assistant Professor of Ophthalmology
    Rocky Mountain Lions Eye Institute
  • Chief of Ophthalmology
    Denver Health

Education

  • M.D.
    The University of Rochester Eye Institute
  • M.B.A.
  • MD
  • MBA
  • medical degree with honors
    University of Colorado School of Medicine
  • M.D.
    University of Rochester Eye Institute - Donald Grover
30 Total References
Web References
David Kleinman, M.D. - University of Rochester Eye Institute - Retina
www.stronghealth.org, 10 Oct 2008 [cached]
David Kleinman, M.D., M.B.A.
...
David M. Kleinman, MD, MBA, FACS is a board certified ophthalmologist with fellowship training in vitreoretinal surgery.Dr. Kleinman received his medical degree with honors and completed a subsequent residency in ophthalmology at the University of Colorado School of Medicine.He then recieved additional training through a fellowship in vitreoretinal surgery at the University of Toronto School of Medicine.Dr. Kleinman is the former Chief of Ophthalmology at Denver Health Medical Center in Denver, Colorado where he also served as Director of Ophthalmic Trauma Services and Assistant Professor of Ophthalmology at the Rocky Mountain Lions Eye Institute.
Besides attending to his clinical practice at the University of Rochester Eye Institute, Dr. Kleinman is President and Co-founder of Eyeon Therapeutics, Inc. a start-up firm developing new treatments for eye diseases.He also serves as a consultant to both large and small ophthalmic pharmaceutical and device companies nationally.
...
Dr. Kleinman's research involves the pharmaceutical treatment of diabetic retinopathy and age related macular degeneration.He has made numerous contributions to clinical and research publications in national and international journals of ophthalmology, and has made presentations throughout the world.In addition, he participated as a surgeon for the Himalayan Cataract Project and served as a staff ophthalmologist for Project ORBIS International, Inc.
Dr. Kleinman sees patients at our Strong Memorial Hospital offices.
Dr. David M. Kleinman, an ...
explorehealth.sentara.com, 26 Mar 2011 [cached]
Dr. David M. Kleinman, an associate professor and retina specialist with the Flaum Eye Institute at the University of Rochester in Rochester, N.Y., described the findings as "unsurprising, but very helpful."
"All scientists are going to say they need more research," he noted.
...
SOURCES: William G. Christen, Ph.D., Sc.D., associate professor, division of preventive medicine, department of medicine, Brigham and Women's Hospital and Harvard Medical School, Boston; David M. Kleinman, M.D., M.B.A., associate professor and retina specialist, Flaum Eye Institute, University of Rochester, Rochester, N.Y.; March 14, 2011, Archives of Ophthalmology, online
The ISTA deal comes as the ...
www.democratandchronicle.com [cached]
The ISTA deal comes as the ophthalmic pharmaceutical market - expected to reach $17 billion globally by 2015, according to Global Industry Analysts Inc. estimates - is growing due to aging populations and the eye problems that come with age, said Dr. David M. Kleinman, associate professor of ophthalmology at the University of Rochester Medical Center and CEO/co-founder of Eyeon Therapeutics Inc.
Before the B+L deal, Valeant Pharmaceuticals International Inc. unsuccessfully sought to purchase ISTA. Last month it purchased the ophthalmic biotechnology company Eyetech Inc. Merck & Co. in 2011 purchased Inspire Pharmaceuticals Inc., which specialized in ophthalmic products. Glaxo-SmithKline and other global pharmaceutical companies continue to look at ophthalmology as good opportunities for meaningful growth, said Kleinman.
B+L earlier this month said it was starting a phase III clinical trial for a pharmaceutical being developed for treatment of glaucoma or ocular hypertension. The drug being tested was developed by French pharmaceutical company NicOx SA, which in 2010 licensed it to B+L.
"You see the large eye companies focusing on pharma acquisitions and licensing because everybody knows there are good treatments for ophthalmic diseases with pharmaceuticals," said Kleinman, who has done some consulting work for B+L.
Strong Health - Homepage
www.stronghealth.org, 21 Aug 2008 [cached]
The University of Rochester Eye Institute welcomes retinal specialist David M. Kleinman, M.D., M.B.A., F.A.C.S., who joins the faculty as an assistant professor of Ophthalmology at the University of Rochester Medical Center.Read More
Artificial Cornea Offers Better Results for Infants, Some Blind Patients
Dr. David M. ...
www.specialtypharma.com, 1 Oct 2012 [cached]
Dr. David M. Kleinman President, CEO & Co-Founder Eyeon Therapeutics, Inc. Dr. David M. Kleinman is President, CEO, and Co-founder of Eyeon Therapeutics, Inc., an early stage ophthalmology firm developing novel technologies to treat eye diseases. Eyeon Therapeutics and Particle Sciences, Inc. have formed a joint venture to commercialize PEGPLUSTM as an improved therapy for dry eye syndrome. Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery, and he also serves as a part-time Associate Professor of Ophthalmology at the Flaum Eye Institute at the University of Rochester. In addition to running Eyeon Therapeutics and working at the Flaum Eye Institute, he consults for biotechnology, medical device, pharmaceutical, and investment firms nationally. He has helped multiple start-ups develop intellectual property, generate preclinical data, raise money, submit regulatory filings, and complete proof-of-principle and Phase I clinical trials. He also assists larger companies with due diligence and pharmaceutical development in ophthalmology. He is the former Chief of Ophthalmology at Denver Health Medical Center in Denver. He earned his BA from Brown University, his MD with honors from the University of Colorado School of Medicine, and graduated as a Dean's Scholar from the Simon School of Business.
Other People with the name "Kleinman":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304